AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$71M

Gross Profit

$66M92.6% margin

Operating Income

-$2M-2.9% margin

Net Income

$2M2.2% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+226.4%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$408M

Total Liabilities

$55M

Stockholders' Equity

$353M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$71M	$0	—
Gross Profit	$66M	$0	—
Operating Income	-$2M	-$48M	+95.7%
Net Income	$2M	-$48M	+103.3%

AMLX Q1 2023 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena